Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132821 · ClinicalTrials.gov registry record · Phase 4
Impact of Smoking Cessation on Sleep - 5
A Phase 4 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT00132821 is a Phase 4 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 59 participants.
The verdict
NCT00132821, a Phase 4 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
Smoking is a major health problem with a direct link to elevated heart- and lung-related problems. Nicotine is highly addictive, which makes quitting difficult and relapse after quitting highly probable. Any type of sleep disturbance may make quitting even harder. The purpose of this study is to evaluate the effect of bupropion and nicotine replacement therapies (NRT) on sleep disturbances. In turn, this might show how such medications affect attempts at smoking cessation.
Interventions
- DRUG Transdermal Nicotine Patch
- DRUG Bupropion
- DRUG Placebo Bupropion
- DRUG Placebo transdermal nicotine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132821
The ClinicalTrials.gov registry entry for NCT00132821 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Transdermal Nicotine Patch is the first listed.
NCT00132821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132821 about?
NCT00132821 is a clinical study titled "Impact of Smoking Cessation on Sleep - 5". Smoking is a major health problem with a direct link to elevated heart- and lung-related problems. Nicotine is highly addictive, which makes quitting difficult and relapse after quitting highly probable. Any type of sleep disturbance may make quitting even harder. The purpose of this study is to eva...
What is the current status of trial NCT00132821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2005-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00132821?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG), Bupropion (DRUG), Placebo Bupropion (DRUG), Placebo transdermal nicotine patch (DRUG).
Who is sponsoring clinical trial NCT00132821?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.